Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Drug Profile

Research programme: serine/threonine protein kinase inhibitors - Onconova Therapeutics

Alternative Names: CDK4 inhibitors - Onconova; ON 108110; ON 108600; ON-123300; ON-150030

Latest Information Update: 24 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Onconova Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai; Onconova Therapeutics
  • Class Antineoplastics; Pyrimidines; Thiazines
  • Mechanism of Action Casein kinase II inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; NUAK1 protein inhibitors; PIM3 protein inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Protein-serine-threonine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Colorectal cancer
  • Research Breast cancer
  • No development reported Cancer

Most Recent Events

  • 19 Apr 2018 Onconova Therapeutics and HanX Biopharmaceuticals announce intention to submit IND application for ON 123300 in USA and China
  • 19 Dec 2017 ON 123300 licensed to HanX Biopharmaceuticals in China
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top